Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bardoxolone Methyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 known ✓ | Q16236 | 3/20 | 1.00 |
| ▸ | KEAP1 known ✓ | Q14145 | 2/20 | 0.83 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 1.00 |
| ▸ | USP7 | Q93009 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | RORC | P51449 | 1/20 | 0.86 |
| ▸ | NOS2 | P35228 | 9/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | CCR6 | P51684 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bardoxolone Methyl SCHEMBL18910897 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL15184347 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL19635256 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL12521530 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL18572802 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL23896957 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL702067 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL21577829 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL22213797 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL25906069 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | Reata Pharmaceuticals Holdings, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11091430-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | REATA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | REATA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10808006-B2 | Sustained-release pharmaceutical composition for treatment and prevention of eye disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2020-09-17 | — | — | US | disclosed |
| US-7915402-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | REATA PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100041904-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | REATA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009023845-A2 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
| WO-2008136838-A1 | NOVEL AMIDE DERIVATIVES OF CDDO AND METHODS OF USE THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080233195-A1 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | TXNRD2, HMOX1, GPX4 | NFE2L2 12/4885KEAP1 60/4885MBOAT4 92/4885 |
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | FECH, KEAP1, NFE2L2 | NFE2L2 3/4885KEAP1 2/4885MBOAT4 4178/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NFE2L2 315/4885KEAP1 444/4885MBOAT4 1458/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | NFE2L2 1455/4885KEAP1 1567/4885MBOAT4 1132/4885 |
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | NFE2L2 9/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NFE2L2 9/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-10808006-B2 | Sustained-release pharmaceutical composition for treatment and prevention of eye disease | KEAP1, NFE2L2, RELA | NFE2L2 2/4885KEAP1 1/4885MBOAT4 3660/4885 |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | HSD11B2, CYP21A2, HSD11B1 | NFE2L2 766/4885KEAP1 694/4885MBOAT4 912/4885 |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | HMOX1, ALOX12, ALOX15 | NFE2L2 4/4885KEAP1 56/4885MBOAT4 650/4885 |
| US-20100041904-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | IL17A, ALOX15, ALOX12 | NFE2L2 6/4885KEAP1 45/4885MBOAT4 500/4885 |
| US-11091430-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | IL17A, ALOX15, ALOX12 | NFE2L2 9/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | CYP17A1, HSD11B2, HSD11B1 | NFE2L2 553/4885KEAP1 207/4885MBOAT4 619/4885 |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | ALOX12, NFE2L2, HMOX1 | NFE2L2 2/4885KEAP1 29/4885MBOAT4 658/4885 |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NFE2L2 9/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | KEAP1, NFE2L2, TFAM | NFE2L2 2/4885KEAP1 1/4885MBOAT4 3834/4885 |
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | HSD11B2, CYP21A2, HSD11B1 | NFE2L2 766/4885KEAP1 694/4885MBOAT4 912/4885 |
| US-20080233195-A1 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH | BMP4, BMP2, BMP1 | NFE2L2 1294/4885KEAP1 2672/4885MBOAT4 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.